Articles related to VACCINES/IMMUNIZATION

The FDA approved updated 2026-2027 formulations of Pfizer-BioNTech, Moderna, and Novavax COVID-19 vaccines targeting the XFG variant, aligning with advisory committee recommendations for the upcoming vaccination season.

Invasive pneumococcal disease declined among US children across vaccine eras, but incidence remained substantially higher among those with chronic medical or immunocompromising conditions, with relative disparities widening over the 25-year claims-based study.

The American Academy of Pediatrics expanded its definition of children at high risk for severe RSV disease who should receive immunization before their second RSV season, adding several congenital, developmental, and prematurity-related conditions to existing eligibility criteria.

A perspective article argues that vaccine-hesitant parents often communicate uncertainty indirectly through delays, scheduling questions, or silence rather than explicit refusal. The author proposes an “announce, detect, switch” framework that warrants prospective evaluation before broader adoption.

The FDA approved Moderna’s mFLUSIVA, the first mRNA influenza vaccine, for adults aged 50 and older. Availability is expected during the 2026–2027 respiratory virus season, with confirmatory evidence pending for adults 65 and older.

A phase 1 study of mKRAS-VAX in 20 patients at high risk for PDAC showed KRAS-specific T-cell responses in most participants. No high-grade adverse events occurred, but clinical prevention data remain early.